2. Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care, 2012, 16(4): R141.
5. Holm A, Pedersen SS, Nexoe J, et al. Procalcitonin versus C-reactive protein for predicting pneumonia in adults with lower respiratory tract infection in primary care. Br J Gen Pract, 2007, 57(540): 555-560.
9. Wacker C, Prkno A, Brunkhorst FM, et al. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis, 2013, 13(5): 426-435.
[10]
10. Prkno A, Wacker C, Brunkhorst FM, et al. Procalcitonin-guided therapy in intensive care unit patients with severe sepsis and septic shock--a systematic review and meta-analysis. Crit Care, 2013, 17(6): R291.
16. Xiao K, Su LX, Han BC, et al. Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study. J Thorac Dis, 2013, 5(5): 626-633.
[17]
17. Zhuang Y, Li W, Wang H, et al. Predicting the outcomes of subjects with severe community-acquired pneumonia using monocyte human leukocyte antigen-DR. Respir Care, 2015, 60(11): 1635-1642.
[18]
18. Kim MW, Lim JY, Oh SH. Mortality prediction using serum biomarkers and various clinical risk scales in community-acquired pneumonia. Scand J Clin Lab Invest, 2017, 77(7): 486-492.